Hadassah head Prof. Zeev Rotstein also got a shot of the Israeli-made vaccine as part of Phase 2 of the clinical trial.
"We are trying to create a blue-and-white vaccine in collaboration with the Biological Institute in Ness Ziona," Rotstein said.
"It is important for me to be among the participants, because we also need those who are not very young and not very healthy, in order to develop and achieve the full results of the research," he added.
Prof. Yossi Karko, director of the Center for Clinical Research at Hadassah and the chief research officer in Israel of Phase 2 of the clinical research of the vaccine, also marked the momentous occasion of the Israeli-made vaccine.
"This is an exciting day; a real milestone. We passed the first stage very successfully and today we are starting the second stage – and I admit we are very excited. It will not be easy but we are going to succeed," Karko added.
"At this stage, we will recruit a total of 960 people across the country, including older people - unlike the first stage," Karko said. "My team is prepared to receive the referrals of anyone interested in participating and helping us with the research, so we can finish it as soon as possible."We are full of hope that this vaccine will be at least as effective and good as the vaccine that has already arrived in Israel."